Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A/H5 Inactivated Monovalent Influenza Vaccines with AS03 or MF59 Adjuvants
NCT06560151Phase 2Completed
- Sponsor
- Biomedical Advanced Research and Development Authority
- Start
- Aug 2024
- Primary completion
- Jan 2025
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines, Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in influenza (15 arms), sponsored by Biomedical Advanced Research and Development Authority. Primary endpoints: Percentage of Participants Who Experience Any Solicited Local Reactogenicity Symptom, Percentage of Participants Who Experience Any Solicited Systemic Reactogenicity Symptom and 1 more. Started Aug 2024; status: completed.
02
Conditions
influenza
Beyond the preview
Go deeper on NCT06560151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06560151.